Table 2. Patient Characteristic by Overall Evidence-Based Composite Score.
Patient characteristics | Evidence-based therapy score, % (95% CI) | |
---|---|---|
0-1 (n = 241 593) | 2-3 (n = 83 113) | |
Age, mean (SD) [95% CI], y | 68.5 (12.6) [68.5-68.6] | 66.7 (10.7) [66.7-66.8] |
Sex | ||
Women | 45.4 (45.2-45.6) | 41.5 (41.2-41.8) |
Men | 54.6 (54.4-54.8) | 58.5 (58.2-58.9) |
Race | ||
Asian | 2.8 (2.8-2.9) | 2.9 (2.8-3.1) |
Black | 17.6 (17.5-17.8) | 19.9 (19.7-20.2) |
White | 64.5 (64.4-64.7) | 62.5 (62.1-62.8) |
Othera | 15.0 (14.9-15.2) | 14.7 (14.4-14.9) |
Latinx ethnicity | 12.3 (12.2-12.5) | 14.0 (13.8-14.3) |
ASCVD | ||
Coronary artery disease | 72.1 (71.9-72.2) | 75.7 (75.4-76.0) |
MI | 22.0 (21.8-22.1) | 29.8 (29.5-30.2) |
PCI | 19.6 (19.4-19.7) | 26.7 (26.37-26.97) |
Cerebrovascular disease | 17.6 (17.4-17.7) | 21.2 (20.96-21.51) |
Stroke | 11.6 (11.5-11.8) | 14.7 (14.46-14.94) |
Peripheral arterial disease | 45.9 (45.7-46.1) | 49.2 (48.90-49.58) |
Comorbidities | ||
Heart failure | 31.0 (30.8-31.2) | 35.3 (35.02-35.67) |
Atrial fibrillation | 21.7 (21.6-21.9) | 20.3 (20.0-20.5) |
Hypertension | 90.7 (90.6-90.8) | 96.4 (96.2-96.5) |
Dyslipidemia | 80.3 (80.2-80.5) | 90.6 (90.4-90.8) |
Smoking | 10.6 (10.4-10.7) | 14.6 (14.4-14.9) |
Charlson Comorbidity Index score, mean (SD) [95% CI] | 4.1 (2.8) [4.1-4.1] | 4.3 (2.8) [4.2-4.3] |
Diabetes complications | ||
Diabetic ketoacidosis | 1.6 (1.5-1.6) | 2.1 (2.1-2.2) |
Retinopathy | 8.3 (8.2-8.5) | 12.4 (12.2-12.6) |
Neuropathy | 24.6 (24.4-24.8) | 31.3 (30.9-31.6) |
Diabetic foot | 5.0 (4.9-5.1) | 5.4 (5.3-5.6) |
SBP, mm Hg (n = 303 859)b | 132 (20) [132-132] | 132 (20) [132-132] |
BMI (n = 295 725)b | 31.0 (7.2) [31.0-31.1] | 32.1 (7.3) [32.1-32.2] |
Laboratory values, mean (SD) [95% CI]b | ||
Cholesterol, mg/dL | ||
LDL (n = 159 903) | 85.0 (35.3) [84.8-85.2] | 80.1 (35.7) [79.8-80.4] |
HDL (n = 142 453) | 47.3 (15.7) [47.2-47.4] | 44.6 (13.9) [44.4-44.7] |
Triglycerides, mg/dL (n = 159 493) | 155.2 (116.1) [154.5-155.9] | 163.3 (125.2) [162.3-164.4] |
HbA1c, % (n = 188 662) | 7.2 (1.7) [7.2-7.2] | 7.3 (1.7) [7.2-7.3] |
eGFR, mL/min/1.73m2 (n = 177 224) | ||
<15 | 6.0 (5.9-6.1) | 3.7 (3.6-3.9) |
15-29 | 7.5 (7.3-7.6) | 4.7 (4.5-4.8) |
30-59 | 34.6 (34.3-34.9) | 34.1 (33.7-34.5) |
≥60 | 51.7 (51.4-52.0) | 57.3 (56.9-57.7) |
Missing | 0.2 (0.2-0.3) | 0.2 (0.1-0.2) |
Geographic region (n = 191 376)b | ||
Northeast | 48.3 (48.1-48.6) | 40.7 (40.3-41.1) |
South | 40.0 (39.8-40.3) | 44.2 (43.8-44.6) |
West | 6.0 (5.9-6.2) | 10.4 (10.2-10.7) |
Other | 0.2 (0.1-0.2) | 0.3 (0.2-0.3) |
Missing | 4.7 (4.6-4.8) | 2.5 (2.4-2.6) |
Insurance coverage (n = 161 874)b | ||
Medicare | 49.5 (49.2-49.8) | 35.7 (35.2-36.2) |
Medicaid | 2.9 (2.8-3.0) | 5.1 (4.9-5.4) |
Military health care | 1.2 (1.2-1.3) | 1.6 (1.4-1.7) |
Private | 12.9 (12.7-13.1) | 9.0 (8.7-9.3) |
State-specific | 0.2 (0.2-0.2) | 0.4 (0.3-0.4) |
Self-pay | 0.8 (0.8-0.9) | 1.8 (1.7-2.0) |
Other | 10.3 (10.1-10.4) | 17.9 (17.5-18.3) |
Missing | 22.2 (22.0-22.4) | 28.5 (28.1-29.0) |
Physicians (n = 205 885)b | ||
Endocrinologist | 8.0 (7.9-8.1) | 11.0 (10.7-11.3) |
Cardiologist | 22.3 (22.1-22.5) | 39.2 (38.8-39.6) |
Primary care | 72.1 (71.9-72.3) | 83.4 (83.1-83.71) |
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure.
SI conversion factors: To convert cholesterol to millimoles per liter, multiply by 0.029; HbA1c to proportion of total hemoglobin, multiply by 0.01; triglycerides to millimoles per liter, multiply by 0.0113.
Other race refers to American Indian, Alaskan Native, Native Hawaiian or other Pacific Islander, or some other nonlisted race that is not Asian, Black, or White.
Completeness varied for specific data elements; therefore the analytic population size is presented where the full cohort was smaller.